Allegro completes enrollment in lung cancer Dx trial

Allegro Diagnostics has reached a major milestone in development of its new BronchoGen molecular diagnostic test for lung cancer: Enrollment is finally complete in the Maynard, MA-company's 1,320-patient AEGIS II clinical trial. Researchers are testing how well BronchoGen works along with a bronchoscopy to detect early signs of lung cancer, compared to a bronchoscopy alone. Data from the trial is expected by mid-2013. Allegro President and CEO Michael Webb told FierceMedicalDevices earlier this summer that the company is working to raise between $15 million and $20 million in Series B financing to help complete clinical testing and fuel an early 2013 commercial launch of the BronchoGen product. Release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.